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In the current issue Kuhlkamp, et al. (1) demonstrate that
patients with ventricular tachyarrhythmias treated with sotalol
have fewer subsequent arrhythmia recurrences than patients
receiving no antiarrhythmic drug. The authors highlight a
second observation that electrophysiologic testing does not
distinguish between efficacy and inefficacy of sotalol. I believe
this latter conclusion is statistically invalid, whereas the former
observation makes this study a milestone.
See page 46
Since the introduction of programmed ventricular stimula-
tion for predicting antiarrhythmic drug efficacy 20 years ago
(2–4) a nagging question had remained unanswered: Does
electrophysiologic testing of drug efficacy simply select patients
with a better prognosis? This uncertainty was recognized early
on:
There are two reasonable explanations for the observed
predictive value of the patient’s response to therapy at electro-
physiologic study. The first is that the administration of therapy
that was predicted to be effective at electrophysiologic study
may prevent fatal arrhythmia. The second is that the response
to therapy at electrophysiologic study may identify patients who
are at lower risk for sudden death, whether they receive the
evaluated therapy or not . . . Since withholding therapy pre-
dicted to be effective from patients who have life-threatening
arrhythmias would be required, such a study may not be
justified (5).
In the early studies (2,4,5) and in all subsequent research on
drug efficacy testing in this high risk population, a drug
predicted to be effective had never been compared to placebo.
But, the speculation that programmed stimulation simply
selects patients with a good prognosis is well founded. Many of
the predictors of a favorable response to drug testing by
programmed stimulation (6) are the same clinical characteris-
tics associated with a better outcome in patients with ventric-
ular arrhythmias and cardiac disease in general.
Soon after introduction of the implantable cardioverter–
defibrillator (ICD) to clinical application 18 years ago, its use
as a safety net to allow comparison of drugs to placebo in
ventricular tachyarrhythmia survivors was envisioned. Remark-
ably, until the work of Kuhlkamp et al. (1), a randomized study
comparing drug to no drug, over the safety net of the ICD, had
not been published. Kuhlkamp and colleagues correctly rea-
soned that it would be ethical (and instructive) to randomize
patients receiving an ICD to receive concomitantly either an
antiarrhythmic drug or no antiarrhythmic drug.
In this study (1) the 93 patients treated with an ICD had
continued arrhythmia inducibility during programmed stimu-
lation while receiving sotalol. The 46 of them who were
randomized to receive long-term therapy with sotalol had
significantly fewer arrhythmia recurrences than the 47 random-
ized to no antiarrhythmic therapy.
Is this beneficial effect unique to sotalol? In a nonrandom-
ized study Kou et al. (7) found that in 33 patients with ICDs
receiving a variety of drugs other than sotalol (predominantly
amiodarone, received by 16 of the 33) the incidence of
appropriate ICD discharges was no lower than that of a
concurrent group of 41 patients receiving no antiarrhythmic
agent. Anderson et al. also found no improvement in defibril-
lator discharge rates in patients receiving antiarrhythmic drugs
exclusive of sotalol (8). There is substantial evidence that
sotalol is more effective than Vaughn Williams Class I antiar-
rhythmic drugs (9) (though it has yet to be compared directly
to amiodarone). In addition, beta-adrenergic antagonists pre-
vent sudden death in patients with a prior myocardial infarc-
tion, and, as noted by Kuhlkamp and colleagues, beta-
adrenergic blocking agents reduce the incidence of
defibrillator shocks. Thus, the beneficial effect could well be
unique to sotalol among antiarrhythmic agents.
This study provides what I consider to be the first conclusive
evidence that an antiarrhythmic drug can reduce the incidence
of sustained ventricular tachyarrhythmias in a high risk popu-
lation (outside of the acute myocardial infarction setting, in
which prevention of ventricular fibrillation [VF] has been
demonstrated previously). However, we cannot conclude that
the effect is a result of a “traditional” ventricular antiarrhyth-
mic effect (class I or class III action) because sotalol’s beta-
blocking property alone could have accounted for the result.
Should all ICD recipients receive concomitant antiarrhyth-
mic therapy? There are a number of potential advantages and
disadvantages. The advantages include reduced arrhythmia
recurrence rate, reduced ventricular tachycardia rate, reduced
spurious discharge rate (in the case of drugs that reduce sinus
rate and the rate of occurrence of supraventricular tachycardia
[SVT] and possibly increased longevity. Disadvantages include
antiarrhythmic drug side effects, including proarrhythmia, and
increased defibrillation threshold. In light of the current study,
for the meantime this question can be narrowed to whether
sotalol should be used in all ICD recipients. Sotalol would
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provide most of the above-mentioned benefits. With regard to
potential adverse effects, sotalol does not increase defibrilla-
tion threshold. In fact, it decreases both ventricular and atrial
defibrillation thresholds (10,11). However, there is no evidence
yet for a survival benefit, and its side effects, especially those
related to beta-blockade, would be problematic for some
patients. Thus, general use of sotalol in ICD recipients (ex-
cluding those with severe congestive heart failure, airways
disease or a propensity to hypokalemia) may or may not have
merit, and I recommend consideration of this issue by the
arrhythmia/electrophysiology community.
The report’s conclusion that sotalol-treated patients with
inducible ventricular tachyarrhythmia/VF have the same prog-
nosis as those with suppression of inducibility is not appropri-
ate. First, only the 93 patients who had continued inducibility
were randomized (and that fact lends to the statistical validity
of the comparison between the sotalol–ICD group and the
ICD-only group). The other 53 patients were not randomized
to receive sotalol, but received it if they had arrhythmia
suppression during programmed stimulation. Thus, the com-
parison between the sotalol group and the sotalol–ICD group
should be viewed as an observational case–control study, with
less authority than a randomized comparison would have.
Second, even if the patients had been randomized, the statis-
tical method used to prove the null hypothesis (no predictive
value of electrophysiologic testing) was incorrect. Demonstrat-
ing equivalence of two treatments is much more demanding
than showing a difference, primarily because the maximum
difference between the two must be set to a small value, usually
10% or less, as compared with the values of 25% to 50%
usually selected for “positive” trials. The methods of Makuch
and Simon (12) and of Blackwell (13), for proving the null
hypothesis that patients on sotalol with and without inducibility
have an equivalent outcome, yield required total samples of
662 and 720 patients, respectively (assuming an overall recur-
rence rate of 30%, an alpha of 0.05, a beta of 0.20 and a 95%
confidence limit for a difference between the two groups of no
greater than 10%), as compared to only 99 subjects in the
current study.
On the basis of the study of Kuhlkamp et al. (1), I strongly
urge future study of other, especially new, antiarrhythmic
drugs over the ICD safety net. On the basis of this study I
cannot recommend abandonment of electrophysiologic study
for prediction of efficacy of sotalol.
The author acknowledges with appreciation the review and recommendations
provided by Drs. R. Freedman, T. Moon, R. Klein and S. Compton.
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Abbreviations and Acronyms
ICD 5 implantable cardioverter–defibrillator
VF 5 ventricular fibrillation
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